To confirm that the involvement of JNK signaling is essential for the RASSF6-promoted sensitivity to chemotherapy and radiotherapy in NPC cells, we applied the JNK inhibitor SP600125 to cells exposed to cisplatin or radiation treatment (Figure 5C). Here, RASSF6 is linked to nasopharyngeal carcinoma.